Cargando…
Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome
Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512040/ https://www.ncbi.nlm.nih.gov/pubmed/34641407 http://dx.doi.org/10.3390/molecules26195863 |
_version_ | 1784582894504640512 |
---|---|
author | Yamagata, Kazuo Yamori, Yukio |
author_facet | Yamagata, Kazuo Yamori, Yukio |
author_sort | Yamagata, Kazuo |
collection | PubMed |
description | Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension, hyperglycemia, and dyslipidemia. Although the health benefits of soybean-derived isoflavones are widely known, their beneficial effects on the pathogenesis of metabolic syndrome are incompletely understood. This review aims to describe the association between soybean-derived isoflavone intake and the risk of metabolic syndrome development. We reviewed studies on soy isoflavones, particularly daidzein and genistein, and metabolic syndrome, using PubMed, ScienceDirect, and Web of Science. We describe the pathological characteristics of metabolic syndrome, including those contributing to multiple pathological conditions. Furthermore, we summarize the effects of soybean-derived daidzein and genistein on metabolic syndrome reported in human epidemiological studies and experiments using in vitro and in vivo models. In particular, we emphasize the role of soy isoflavones in metabolic syndrome-induced cardiovascular diseases. In conclusion, this review focuses on the potential of soy isoflavones to prevent metabolic syndrome by influencing the onset of hypertension, hyperglycemia, dyslipidemia, and arteriosclerosis and discusses the anti-inflammatory effects of isoflavones. |
format | Online Article Text |
id | pubmed-8512040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85120402021-10-14 Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome Yamagata, Kazuo Yamori, Yukio Molecules Review Isoflavones are polyphenols primarily contained in soybean. As phytoestrogens, isoflavones exert beneficial effects on various chronic diseases. Metabolic syndrome increases the risk of death due to arteriosclerosis in individuals with various pathological conditions, including obesity, hypertension, hyperglycemia, and dyslipidemia. Although the health benefits of soybean-derived isoflavones are widely known, their beneficial effects on the pathogenesis of metabolic syndrome are incompletely understood. This review aims to describe the association between soybean-derived isoflavone intake and the risk of metabolic syndrome development. We reviewed studies on soy isoflavones, particularly daidzein and genistein, and metabolic syndrome, using PubMed, ScienceDirect, and Web of Science. We describe the pathological characteristics of metabolic syndrome, including those contributing to multiple pathological conditions. Furthermore, we summarize the effects of soybean-derived daidzein and genistein on metabolic syndrome reported in human epidemiological studies and experiments using in vitro and in vivo models. In particular, we emphasize the role of soy isoflavones in metabolic syndrome-induced cardiovascular diseases. In conclusion, this review focuses on the potential of soy isoflavones to prevent metabolic syndrome by influencing the onset of hypertension, hyperglycemia, dyslipidemia, and arteriosclerosis and discusses the anti-inflammatory effects of isoflavones. MDPI 2021-09-27 /pmc/articles/PMC8512040/ /pubmed/34641407 http://dx.doi.org/10.3390/molecules26195863 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yamagata, Kazuo Yamori, Yukio Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title | Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title_full | Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title_fullStr | Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title_full_unstemmed | Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title_short | Potential Effects of Soy Isoflavones on the Prevention of Metabolic Syndrome |
title_sort | potential effects of soy isoflavones on the prevention of metabolic syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512040/ https://www.ncbi.nlm.nih.gov/pubmed/34641407 http://dx.doi.org/10.3390/molecules26195863 |
work_keys_str_mv | AT yamagatakazuo potentialeffectsofsoyisoflavonesonthepreventionofmetabolicsyndrome AT yamoriyukio potentialeffectsofsoyisoflavonesonthepreventionofmetabolicsyndrome |